3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
55
Lung Neoplasms
22
Neoplasms
4
Neoplasm Metastasis
3
Carcinoma
3
Breast Neoplasms
3
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Multiple Myeloma
2
Lymphoma
2
Hematologic Neoplasms
2
Colorectal Neoplasms
2
Brain Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Stage IB-IIIA Non-small Cell Lung Carcinoma
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor
1
Rectal Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder)
1
Non Small Cell Lung Cancer Metastatic
1
NSCLC
1
Multiple Endocrine Neoplasia Type 2a
1
Mesothelioma
1
Interventions
Platinum
6
Cisplatin
6
Pemetrexed
5
1,2-diaminocyclohexaneplatinum II citrate
5
pembrolizumab
4
atezolizumab
3
Radiotherapy
2
Radiation
2
Nivolumab
2
Ipilimumab
2
Gemcitabine
2
Cyclophosphamide
2
Carboplatin
2
tremelimumab
1
methoxyamine
1
fludarabine
1
decitabine and cedazuridine drug combination
1
cediranib
1
anetumab ravtansine
1
aldesleukin
1
Trioxsalen
1
Tissue Banks
1
Radiotherapy, Intensity-Modulated
1
Proton Therapy
1
Phototherapy
1
Photochemotherapy
1
Pharmacogenomic Testing
1
Pharmaceutical Preparations
1
Interleukin-2
1
Influenza Vaccines
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Mesothelioma, Malignant
×
osimertinib
×
90 days
×
Clear all
No trials found.